Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | SCN1A | P35498 | 2/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.31 |
| ▸ | WNK1 | Q9H4A3 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502649 | 0.89 | ATR (0.32) | RXRARXRBRXRGJAK1MCHR1 | |
| SCHEMBL6505150 | 0.88 | MAP3K8 (0.33) | RXRARXRBRXRGMEN1KMT2A | |
| SCHEMBL6508798 | 0.85 | RXRA (0.32) | RXRARXRBRXRG | |
| SCHEMBL6508973 | 0.83 | RXRA (0.32) | RXRARXRBRXRG | |
| SCHEMBL6505430 | 0.83 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL6508264 | 0.82 | RAB9A (0.34) | RXRARXRBRXRG | |
| SCHEMBL6508398 | 0.81 | RXRA (0.31) | RXRARXRBRXRG | |
| SCHEMBL6503077 | 0.80 | PFKFB3 (0.32) | MCHR1 | |
| SCHEMBL6510743 | 0.79 | CNR2 (0.31) | RXRARXRBRXRG | |
| SCHEMBL6500872 | 0.79 | BTK (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | RXRA 2748/4885RXRB 2441/4885RXRG 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.